Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05917132
Other study ID # 2022-109
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 12, 2023
Est. completion date June 12, 2025

Study information

Verified date December 2023
Source Laval University
Contact Alain Veilleux, PhD
Phone 418 656-3527
Email alain.veilleux@fsaa.ulaval.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed project mainly aims to investigate the microbial processes leading to dietary metabolites production, independently of long-term microbiota adaptation to the diet, by measuring the microbiota-derived metabolite production from a meal sequence rich in saturated fatty acids (SFA) or the same meals but rich in polyunsaturated fatty acids (PUFA) in individuals with or without obesity and Type 2 diabetes (T2D)


Description:

The gut microbiota interacts with the host's enteric and systemic functions through the production of gut microbiota-derived metabolites. A subset of these metabolites, the endocannabinoids (eCB) and their congeners are derived from fatty acids and play a crucial role in metabolic health. The research project aims to study gut microbiota-derived metabolites, including the eCB and their congeners, in response to a 2-day diet rich in polyunsaturated fatty acids or rich in saturated fatty acids in individuals with or without abdominal obesity and type 2 diabetes. The investigators hope to better understand the kinetic production of circulating endocannabinoidome mediators derived from fatty acids in the diet.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 12, 2025
Est. primary completion date June 12, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria: - Men and women aged between 45 and 65 years, menopaused women ; - Body mass index between 20 to 35 kg/m² ; - General good health ; - Score of diet quality (HEI) between 40 and 70 ; - Computer and Internet access ; - Basic understanding of written French ; - Daily stool frequency. Exclusion Criteria: - Intestinal pathologies including inflammatory bowel disease and gastrointestinal cancers ; - Alcohol consumption greater than 15 portions for men and 10 for women weekly. - Active tobacco and cannabis usage ; - Consumption of omega-3 dietary supplements ; - Consumption of dietary supplements (vitamins and probiotics) - must be ceased 2 weeks before the dietary intervention ; - Completion of a course of antibiotics in the past 3 months ; - Important weight change (+/- 5 kg) in the past 6 months ; - Type 1 diabetes or insulin-treated diabetes.

Study Design


Intervention

Other:
Nutritionnal intervention
Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.

Locations

Country Name City State
Canada Institut sur la nutrition et les aliments fonctionnels - INAF Québec Quebec

Sponsors (1)

Lead Sponsor Collaborator
Laval University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fasting and postprandial lipid metabolite production in response to dietary lipid intervention in abdominal obesity and type 2 diabetes Interindividual variations in the endocannabinoidome mediators levels following a 2-day SFA and UFA diet intervention according to abdominal adiposity and type 2 diabetes. 7 days
Secondary Gut microbiota in response to a 2 day dietary lipid intervention in abdominal obesity and type 2 diabetes Interindividual variations in the gut microbiota composition following a 2-day SFA and UFA diet intervention according to abdominal adiposity and type 2 diabetes. 7 days
See also
  Status Clinical Trial Phase
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT04877548 - Powdered Fermented Fruits for Glycemia Reduction N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Recruiting NCT04043520 - Bioenergetic Effects of Aging and Menopause (BEAM) Phase 4
Completed NCT02217423 - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy N/A
Completed NCT06290674 - Extracorporeal Shockwave on Abdominal Adiposity and Lipid Profile N/A
Not yet recruiting NCT05004558 - Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias N/A
Completed NCT04621032 - Obstructive Sleep Apnea Destabilizes Myocardial Repolarization Homogeneity
Completed NCT03347604 - Effect of Body Position on Spirometry in Abdominal Obesity.
Completed NCT02654535 - Meta-analyses of Nuts and Risk of Obesity
Completed NCT03805516 - Central Obesity and Cancer Prevention for Chinese American Women N/A
Completed NCT03523403 - Obesity-related Health Benefits of Apples N/A
Terminated NCT03700827 - Effects of Aerobic and Resistance Training on Abdominal Fat Loss N/A
Terminated NCT03138369 - Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
Completed NCT01716819 - Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity N/A
Completed NCT05612282 - The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and the Level of Cardiopulmonary Fitness
Terminated NCT03115385 - Probiotics and the Gut Microbiome in Obese Hispanic Youth N/A
Completed NCT04911582 - Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy) N/A
Completed NCT04754464 - Clinical Study on the Effect of a Synbiotic on Body Fat Mass N/A